He Yu, Ge Yugang, Jiang Mingkun, Zhou Jundong, Luo Dakui, Fan Hao, Shi Liang, Lin Linling, Yang Li
Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Suzhou Cancer Center Core Laboratory, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, China.
Cell Physiol Biochem. 2018;47(4):1465-1481. doi: 10.1159/000490839. Epub 2018 Jun 21.
BACKGROUND/AIMS: Gastric cancer (GC) is one of the most prevalent digestive malignancies. MicroRNAs (miRNAs) are involved in multiple cellular processes, including oncogenesis, and miR-592 itself participates in many malignancies; however, its role in GC remains unknown. In this study, we investigated the expression and molecular mechanisms of miR-592 in GC.
Quantitative real-time PCR and immunohistochemistry were performed to determine the expression of miR-592 and its putative targets in human tissues and cell lines. Proliferation, migration, and invasion were evaluated by Cell Counting Kit-8, population doubling time, colony formation, Transwell, and wound-healing assays in transfected GC cells in vitro. A dual-luciferase reporter assay was used to determine whether miR-592 could directly bind its target. A tumorigenesis assay was used to study whether miR-592 affected GC growth in vivo. Proteins involved in signaling pathways and the epithelial-mesenchymal transition (EMT) were detected with western blot.
The ectopic expression of miR-592 promoted GC proliferation, migration, and invasion in vitro and facilitated tumorigenesis in vivo. Spry2 was a direct target of miR-592 and Spry2 overexpression partially counteracted the effects of miR-592. miR-592 induced the EMT and promoted its progression in GC via the PI3K/AKT and MAPK/ERK signaling pathways by inhibiting Spry2.
Overexpression of miR-592 promotes GC proliferation, migration, and invasion and induces the EMT via the PI3K/AKT and MAPK/ERK signaling pathways by inhibiting Spry2, suggesting a potential therapeutic target for GC.
背景/目的:胃癌(GC)是最常见的消化系统恶性肿瘤之一。微小RNA(miRNA)参与多种细胞过程,包括肿瘤发生,且miR-592自身参与许多恶性肿瘤;然而,其在胃癌中的作用仍不清楚。在本研究中,我们调查了miR-592在胃癌中的表达及分子机制。
采用定量实时PCR和免疫组化法测定miR-592及其假定靶点在人组织和细胞系中的表达。通过细胞计数试剂盒-8、群体倍增时间、集落形成、Transwell和划痕愈合试验在体外转染的胃癌细胞中评估增殖、迁移和侵袭。采用双荧光素酶报告基因试验确定miR-592是否能直接结合其靶点。采用肿瘤发生试验研究miR-592是否影响体内胃癌生长。用蛋白质印迹法检测参与信号通路和上皮-间质转化(EMT)的蛋白质。
miR-592的异位表达促进体外胃癌细胞的增殖、迁移和侵袭,并促进体内肿瘤发生。Spry2是miR-592的直接靶点,Spry2的过表达部分抵消了miR-592的作用。miR-592通过抑制Spry2,经由PI3K/AKT和MAPK/ERK信号通路诱导胃癌中的EMT并促进其进程。
miR-592的过表达通过抑制Spry2,经由PI3K/AKT和MAPK/ERK信号通路促进胃癌的增殖、迁移和侵袭并诱导EMT,提示其可能是胃癌的一个潜在治疗靶点。